@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix nt: .
@prefix xsd: .
@prefix orcid: .
@prefix nkg: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
schema:possibleTreatment sub:medtherapy .
sub:medtherapy prov:wasDerivedFrom sub:quote;
schema:drug ;
schema:targetPopulation sub:targetpop;
nkg:indicationType nkg:AdjunctiveTherapy .
sub:quote prov:value "Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.";
prov:wasQuotedFrom .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "UTEeHwYfV6inHkcTx2niWTf7Ohg0EvKibWcmaNMj3Ihdt6p0yT4KiP1ugQM8N7TQQjuPVFGUpRv9fQOyBuq4cQK+AFZYnqJI21Klqou6PhLmHl9MnO4AbKImtxWzY85mKAUSBk1fu/Stn3+g8MzsxUK+trpMUv65C19FOkK6OQo=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-04-03T11:32:11.095+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}